Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with high‐dose cisplatin

BACKGROUND: Highly emetogenic chemotherapy induces emesis in cancer patients without prophylaxis. The purpose of this study was to evaluate the efficacy and safety of a fosaprepitant‐based triple antiemetic regimen for the prevention of chemotherapy‐induced nausea and vomiting (CINV) in patients wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Yuanyuan, Zhao, Bing, Chen, Gang, Chen, Yinlan, Liao, Zijun, Zhang, Haiming, Feng, Weineng, Li, Yinyin, Weng, Heng, Li, Weidong, Zhou, Yuefen, Ren, Biyong, Lu, Yanda, Chen, Jianhua, Liu, Zhenteng, Su, Zhenzhong, Wang, Wenliang, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926955/
https://www.ncbi.nlm.nih.gov/pubmed/36545810
http://dx.doi.org/10.1002/cac2.12397

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9926955/
https://www.ncbi.nlm.nih.gov/pubmed/36545810
http://dx.doi.org/10.1002/cac2.12397

Ejemplares similares